Effectiveness of Booster Measles-Mumps-Rubella Vaccination in Lower COVID-19 Infection Rates: A Retrospective Cohort Study in Turkish Adults

Effectiveness of Booster Measles-Mumps-Rubella Vaccination in Lower COVID-19 Infection Rates: A Retrospective Cohort Study in Turkish Adults

Erhan Yengil,1 Yusuf Onlen,2 Cahit Ozer,1 Mustafa Hambolat,3 Mehmet Ozdogan4 1Department of Family Medicine, Hatay Mustafa Kemal University School of Medicine, Hatay, Turkey; 2Department of Infectious Disease and Clinical Microbiology, Hatay Mustafa Kemal University School of Medicine, Hatay, Turkey...

Full description

Bibliographic Details
Main Authors:	Yengil E, Onlen Y, Ozer C, Hambolat M, Ozdogan M
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-05-01
Series:	International Journal of General Medicine
Subjects:	covid-19 live attenuated vaccines booster vaccination mmr.
Online Access:	https://www.dovepress.com/effectiveness-of-booster-measles-mumps-rubella-vaccination-in-lower-co-peer-reviewed-fulltext-article-IJGM

Similar Items

Two cases of measles after vaccination with measles mumps and rubella combined live attenuated vaccine
by: SHEN Jinhua, et al.
Published: (2022-05-01)

Implementation of the preventive vacc ination program against measles, mumps, and rubella (MMR) on the example of a selected clinic in the city of Krakow
by: Marek Wojczyk, et al.
Published: (2020-06-01)

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
by: Kayla E. Hanson, et al.
Published: (2023-04-01)

Mumps vaccine effectiveness of a 3rd dose of measles, mumps, rubella vaccine in school settings during a mumps outbreak -- Arkansas, 2016-2017
by: Angela Guo, et al.
Published: (2023-12-01)

Immunity to rubella: an Italian retrospective cohort study
by: Francesco Paolo Bianchi, et al.
Published: (2019-11-01)

Association Between Subnational Vaccine Coverage, Migration, and Incident Cases of Measles, Mumps, and Rubella in Iraq, 2001–2016
by: Haley Comfort, et al.
Published: (2022-01-01)

Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study
by: Epiphane Kolla, et al.
Published: (2022-11-01)

Body Mass Index and Antibody Persistence after Measles, Mumps, Rubella and Hepatitis B Vaccinations
by: Marco Fonzo, et al.
Published: (2022-07-01)

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
by: Maddalena Casale, et al.
Published: (2021-05-01)

Associations of adaptive immune cell subsets with measles, mumps, and Rubella−Specific immune response outcomes
by: Lin Wang, et al.
Published: (2023-12-01)

A Case of Genital and Extragenital Warts Unresponsive to Immunotherapy Using Measles, Mumps, Rubella Vaccine
by: Achdiat PA, et al.
Published: (2023-11-01)

A study to evaluate the role of intradermal and intralesional measles, mumps, rubella (MMR) vaccine in treatment of common warts
by: Pragya Gupta, et al.
Published: (2020-01-01)

Clinical safety issues of measles, mumps and rubella vaccines
by: M.A. Afzal, et al.
Published: (2000-01-01)

Stability Study of Measles AIK-C Strain, Mumps RS-12 Strain and Rubella Takahashi Strain in MMR Vaccine
by: Soleimani, S.
Published: (2016-03-01)

Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India
by: S Mangarule, et al.
Published: (2022-08-01)

Intralesional measles, mumps and rubella vaccine versus formic acid puncture in the treatment of common warts: A prospective randomised study
by: Myfanwy J D'Souza, et al.
Published: (2023-01-01)

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA
by: Amy Parker Fiebelkorn, et al.
Published: (2013-09-01)

Voluntary termination of pregnancy: An opportunity for Measles, Mumps and Rubella vaccination in an Italian healthcare local unit
by: V. Pettinicchio, et al.
Published: (2018-04-01)

The Oncogenic Human Papillomavirus Involvement as a Risk Factor of Measles, Mumps, and Rubella Vaccine Immunotherapy Failure in Anogenital Warts
by: Achdiat PA, et al.
Published: (2025-01-01)

Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial
by: Dorthe Maria Vittrup, et al.
Published: (2020-12-01)

Measles, mumps and rubella vaccination coverage in capitals and interior region municipalities of Northeast Brazil: a household survey in a cohort of children born in 2017 and 2018
by: Adjoane Mauricio Silva Maciel, et al.
Published: (2024-12-01)

Hubungan vaksin Measles, Mumps, Rubella (MMR) dengan Kejadian Autisme
by: Elsye Souvriyanti, et al.
Published: (2016-12-01)

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin
by: Andrea A. Berry, et al.
Published: (2017-07-01)

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
by: Md Ahsan Habib, et al.
Published: (2023-01-01)

Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina
by: Carla Vizzotti, et al.
Published: (2023-03-01)

Evaluation of efficacy and safety of intralesional vitamin D3 in comparison with intralesional measles, mumps and rubella (MMR) vaccine in the treatment of multiple cutaneous warts
by: Vijay Deepak Joshi, et al.
Published: (2024-05-01)

Using Real-Time RT-PCR Reagent Kits for Identity Testing of Measles, Mumps and Rubella Vaccines
by: A. S. Binyatova, et al.
Published: (2018-12-01)

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
by: The MMR-162 Study Group
Published: (2018-12-01)

Seroepidemiology of Measles, Mumps and Rubella on Bonaire, St. Eustatius and Saba: The First Population-Based Serosurveillance Study in Caribbean Netherlands
by: Regnerus A. Vos, et al.
Published: (2019-10-01)

Loss of protective immunity of two-dose mumps-containing vaccine over time: concerns with the new strategy of the mumps immunization program in China
by: Danni Wang, et al.
Published: (2021-07-01)

Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years
by: Yukai Zhang, et al.
Published: (2022-04-01)

Response to third rubella vaccine dose
by: Lotta Siira, et al.
Published: (2018-10-01)

Mumps Vaccine Effectiveness Against Orchitis
by: Susan Hahné, et al.
Published: (2012-01-01)

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
by: Jeffrey E. Gold, et al.
Published: (2020-12-01)

Measles - an old children's disease to remember
by: Marta Custódio, et al.
Published: (2018-09-01)

Impact of Measles Vaccination on the Acquisition and Frequency of Measles Infection in Province of Sindh
by: Ammarah Jamal, et al.
Published: (2017-12-01)

Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults
by: Patricia Kaaijk, et al.
Published: (2022-01-01)

Measles - a disease that should be a thing of the past, but returns
by: Katarzyna Głowacka, et al.
Published: (2019-04-01)

Measles - a disease that should be a thing of the past, but returns
by: Katarzyna Głowacka, et al.
Published: (2019-04-01)

Evaluation of the efficacy of intralesional measles, mumps, and rubella vaccine with intralesional Vitamin D3 as immunotherapies in the treatment of recalcitrant cutaneous warts in adult- A randomized placebo-controlled study
by: Alpana Mohta, et al.
Published: (2021-01-01)